Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation.
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation.
复制标题
免疫检查点抑制剂引起的炎症:从临床数据到转化研究。
DOI:
10.3389/fonc.2020.01785
复制
发表时间:
2020
影响因子:
4.7
通讯作者:
Wang J
中科院分区:
文献类型:
--
作者:
Zhu S;Fu Y;Zhu B;Zhang B;Wang J
Immune checkpoint inhibitors (ICIs) have been applied to clinical practice and achieved significant therapeutic benefit in a variety of human malignancies. These drugs not only enhance the body’s antitumor immune response but also produce side effects called immune-related adverse events (irAEs). Although checkpoint inhibitor pneumonitis (CIP) has a low clinical incidence, it is likely to cause the delay or termination of immunotherapy and treatment-related death in some severe cases. An increasing number of CIP cases have been reported since 2015, which are attributed to the augmentation of approvals and uses of ICIs, but a comprehensive understanding of CIP is still lacking. This review focuses on the epidemiology, clinical characteristics, treatment strategies, and underlying mechanisms of CIP to strengthen the recognition of pulmonary toxicity among clinicians and researchers.
登录
查看更多内容
DOI:
10.2169/internalmedicine.8271-16
发表时间:
2017-09-01
期刊:
Internal medicine (Tokyo, Japan)
影响因子:
--
作者:
Ishiwata T;Ebata T;Iwasawa S;Matsushima J;Ota S;Nakatani Y;Tsushima K;Tada Y;Tatsumi K;Takiguchi Y
通讯作者:
Takiguchi Y
影响因子:
10.9
作者:
Addeo, Alfredo;Obeid, Michel;Friedlaender, Alex
通讯作者:
Friedlaender, Alex
影响因子:
5.8
作者:
Franzen, Daniel;Schad, Karin;Kohler, Malcolm
通讯作者:
Kohler, Malcolm
影响因子:
3.2
作者:
Jodai, Takayuki;Yoshida, Chieko;Tomita, Yusuke
通讯作者:
Tomita, Yusuke
影响因子:
28.5
作者:
Li H;Ma W;Yoneda KY;Moore EH;Zhang Y;Pu LL;Frampton GM;Molmen M;Stephens PJ;Li T
通讯作者:
Li T